2017 News Releases

Investor Relations / Media Contact:
Stephen Mock
Senior Vice President, Investor Relations and Corporate Affairs
845-364-4833

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013 | 2012
Mar 14, 2017
Endo Statement On FDA Advisory Committees' Vote Related To OPANA® ER
Mar 03, 2017
Endo International plc To Delist Ordinary Shares From The Toronto Stock Exchange
Feb 28, 2017
Endo Reports Fourth-Quarter And Full-Year 2016 Financial Results
Feb 24, 2017
Endo Pharmaceuticals Inc. Issues Voluntary Nationwide Recall for One Lot of Edex® (alprostadil for injection) 10 mcg 2 Pack Carton Due to Potential Lack of Sterility Assurance
Feb 13, 2017
Endo to Announce Fourth-Quarter and Full-Year 2016 Financial Results
Jan 30, 2017
Endo Announces U.S. FDA Approval of Ephedrine Sulfate Injection, USP
Jan 26, 2017
Endo Announces Actions to Drive Greater Efficiency and Business Alignment
Jan 23, 2017
Endo Announces Agreement to Resolve Federal Trade Commission Investigation and Litigation
Print Page Print Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts | IR Contacts IR Contacts | Financial Tear Sheet Financial Tear Sheet